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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is the 
fourth cause of cancer death with an overall survival 
of 5% at five years. The development of PDAC is 
characteristically associated to the accumulation of 
distinctive genetic mutations and is preceded by 
the exposure to several risk factors. Epidemiology 
has demonstrated that PDAC risk factors may be 
non-modifiable risks (sex, age, presence of genetic 
mutations, ethnicity) and modifiable and co-morbidity 
factors related to the specific habits and lifestyle. 
Recently it has become evident that obesity and 
diabetes are two important modifiable risk factors for 
PDAC. Obesity and diabetes are complex systemic and 
intertwined diseases and, over the years, experimental 
evidence indicate that insulin-resistance, alteration of 
adipokines, especially leptin and adiponectin, oxidative 
stress and inflammation may play a role in PDAC. 
Peroxisome proliferator activated receptor-γ (PPARγ) is 
a nuclear receptor transcription factor that is implicated 
in the regulation of metabolism, differentiation and 
inflammation. PPARγ is a key regulator of adipocytes 
differentiation, regulates insulin and adipokines 
production and secretion, may modulate inflammation, 
and it is implicated in PDAC. PPARγ agonists are used 
in the treatment of diabetes and oxidative stress-
associated diseases and have been evaluated for the 
treatment of PDAC. PPARγ is at the cross-road of 
diabetes, obesity, and PDAC and it is an interesting 
target to pharmacologically prevent PDAC in obese and 
diabetic patients.
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Core tip: Pancreatic cancer has a dismal prognosis with 
an overall five years survival less than 5%. Obesity 
and diabetes are risk factors of pancreatic ductal 
adenocarcinoma (PDAC) increasing the likelihood of its 
development. Agonists of one specific nuclear receptor 
transcription factor, the peroxisome proliferator-
activated receptor γ (PPARγ), are currently used or 
evaluated for the treatment of these diseases. PPARγ 
is a well-known protein implicated in the regulation of 
metabolism, inflammation, and differentiation; standing 
at the cross-road of these diseases it may be a key 
factor linking PDAC to diabetes and obesity, a master 
regulator whose modulation could be the key for PDAC 
treatment.
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INTRODUCTION
The nuclear receptor transcription factors (NR) are a 
group of evolutionary conserved proteins that double 
as receptors and regulators of gene transcription. NR 
regulate the mRNA transcription binding to specific 
sequences of DNA, called hormone-response element 
or HRE[1-3].
NR are ligand activated transcription factors sharing 
a high degree of structural homology and are classified 
according to the sequence homology in six different 
families. The first NR was identified by a group guided 
by Prof. Evans in 1985[4] and was described as a 
glucocorticoid receptor possessing a DNA binding 
domain (DBD) and a ligand binding domain (LBD); 
the two regions, as their names evidently suggest, 
are necessary for the recognition of HRE and for the 
binding to the ligands, respectively. Interestingly, these 
two distinguishing features of a NR, are present in all 
but two receptors, DAX-1 and SHP, who lack the DBD 
and are classified in the newly introduced NR0 seventh 
family of NR[1].
Besides this homology classification, two parallel 
systems are used to aggregates NR: one is based on 
the functional status and localization before the binding 
to the ligand and one on the existence of ligands. 
NR are classified in type Ⅰ, Ⅱ, Ⅲ, or Ⅳ depending 
if they act as homodimers (Ⅰ and Ⅲ), heterodimers 
(Ⅱ) or monomers (Ⅳ); type Ⅲ receptors differ 
from type Ⅰ for the cell localization before the ligand 
binding: type Ⅰ are cytosolic whereas type Ⅲ are 
nuclear[1].
Of the 48 NR identified, for only half there is a 
known ligand, whereas the other half is indicated 
as being “orphan”. The number of orphan receptors 
has changed over time due to identification for some 
of them of a specific natural ligand: orphan nuclear 
receptors with an identified ligand are classified 
as “adopted”. NR are implicated in almost every 
physiological and pathological condition and several 
nuclear receptors are associated to neoplasm in 
several organs and in PDAC[5-9]. Of the numerous 
NR we will focus our attention on the peroxisome 
proliferator-activated receptor (PPAR)-γ, a member of 
the PPAR group of nuclear receptors, strongly tied to 
diabetes, obesity and pancreatic cancer (PC) (Figure 1).
PPAR: an introduction 
Peroxisomes are cellular organelles identified in the 
late 1960 in rat liver[10,11]; single-membrane bound, 
they are involved in cellular functions ranging from 
fatty acid metabolism and transport to reactive oxygen 
species (ROS) detoxification[11]. Clofibrate, a hypo-
lipidemic agent, was the first of a series of peroxisome 
proliferators, molecules capable of inducing the 
“proliferation” of peroxisomes. The first receptor of 
these peroxisome proliferators, generically named 
PPAR, was discovered by Issemann Ⅰ in the 1990[12]; 
in 1992, the number of identified PPARs increases to 
three after the characterization in the frog Xenopus 
of three novel receptors activated by peroxisome 
proliferators and by agents causing carcinogenesis in 
rodent liver; these receptors acted as transcriptional 
activators of the acyl coenzyme A oxidase gene, which 
encodes the key enzyme of peroxisomal fatty acid 
β-oxidation[13].
PPARs belong to the thyroid-like NR1C group of 
nuclear receptors transcription factors[3]; so far the 
group comprises three genes, localized in different 
chromosomes encoding for different transcripts and 
proteins: PPARγ (NR1C3), PPARα (NR1C1) and PPARβ/
δ (NR1C2). PPARs are common finding in human cells; 
indeed whereas PPARγ and PPARβ/δ are ubiquitous, 
PPARα is more expressed in the liver, hearth and 
kidney where β-oxidation is higher[14,15]. The PPARs 
share the classical features of the nuclear receptor 
transcription factor prototyped by the Steroid receptor, 
with some exceptions[1,5,16]: they possess a LBD at 
the C-terminal and a DBD towards the N-terminal, 
separated by a hinge region. Interestingly, only PPARγ 
is expressed as multiple proteins transcribed starting 
from several distinct transcripts[16-18]. Overall the three 
NR show an 80% homology, and are more divergent in 
the LBD, a finding that explain the different response 
to ligands[15,16,19]. Differently from steroid hormones 
receptors, that are “Type Ⅰ” NR, PPARs are type Ⅱ 
NR meaning that they works in tandem as obligatory 
heterodimers with retinoid-X-receptors (RXR-α/β/γ, 
NR2B1/2/3)[3,20-22]: when the NR bind a ligand the 
dimers, localized in the cell nuclei, undergo a transition 
of three dimensional configuration and recognize 
specific HRE, named PPAR response elements (PPRE), 
in the promoters of target genes resulting in their 
activation or repression. PPRE sequences are direct 
repeats of two six nucleotide-long core sequences 
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(AGGTCA) separated by a single nucleotide (DR1): this 
motif was identified by study on DNA sequences bound 
by PPAR and may not represent the exact response 
element[23,24]. Furthermore additional features of the 
consensus sequence have been described such as the 
presence of a specific six nucleotide long sequence 
upstream of the PPRE and it has been demonstrated 
that PPAR may bind also to imperfect PPRE motif[23]. 
Nonetheless, in the ligand-activated PPAR:RXR 
heterodimers, PPAR bind the 5’ end of the DR1, 
whereas RXR bind to the other half; this peculiarity, 
in association with the asymmetric nature of the DR1, 
determines that the dimers act only unidirectionally on 
one DNA strand, although the same complex may bind 
the other DNA strand too. 
PPAR mechanisms of action are not limited to 
activation/repression of target genes, but other 
functions have been described (see later for details). 
Interestingly, PPARs transcriptional activity is not only 
modulated by PPAR ligands, but by ligands of RXR too, 
such as retinoic acid[15,19]. 
Finally, the ligand-binding, that is associated to the 
above mentioned change of the three-dimensional 
configuration of the receptors, determines also the 
attachment of co-activators and detachment of co-
repressors proteins, adding an additional layer of 
complexity to the regulation of PPARs functions 
(see[25] for details). One of the more studied PPAR 
co-activators is PGC-1 that is apparently implicated 
in adiponectin signaling[26,27], but other co-activators 
are steroid receptor co-activator 1, p300, and CREB 
binding protein[27,28]; all of them are tightly involved 
in regulation of metabolism and cancer development. 
Usually PPAR are packed with RXR and co-repressor 
molecules in PPRE and the co-repressors detach after 
ligand binding: in this way PPARs exert their activation 
and repression role. Interestingly, PPARs may regulate 
gene expression and molecular pathway by other 
mechanisms such as transrepression, an inhibitory 
action that is independent from DNA binding: these 
mechanisms are usually associated to secondary 
modifications of the receptors and are relevant for 
regulation of inflammation[5,15,19,29,30].
PPARγ
PPARG is encoded by a single gene located on 
chromosome 3p24, spanning a chromosomal region 
more than 150 kb. The gene is composed by 9 exons 
that give rise to at least 7 transcripts according 
to[16-18] although a survey on ensembl.org suggests 
the existence of up to 14 possible transcripts, 10 of 
them possibly protein-coding. Excepting three recently 
discovered transcripts[16,17], all the transcripts share the 
last 6 exons of the gene (called exons 1-6) and are 
produced by use of alternative promoters and different 
5’ exons (called, from the 5’ end of the gene, A1, A2 
and B). Nonetheless, for a long time only two proteins 
were believed to be produced by PPAR: PPARγ1 and 
PPARγ2.
PPARγ2 differs from PPARγ1 for the addition of 28 



































Figure 1  Effects of peroxisome proliferator-activated receptor-γ on diabetes, obesity, and pancreatic ductal adenocarcinoma. The nuclear receptor PPARγ 
may directly inhibit tumor growth and metastatization and it is implicated in PSC activation. PPARγ activation may increase insulin secretion and production in β-cells, 
and may increase insulin-sensitivity in peripheral tissue. PPARγ induces differentiation of pre-adipocytes in new small adipocytes that are more insulin-sensitive and 
produce lower amount of inflammatory adipokines. Finally, PPARγ may directly and indirectly (modulating adiponectin and leptin levels) inhibit inflammation altering 
the level of adiponectin and leptin. FFA: Free fatty acids; PPARγ: Peroxisome proliferator-activated receptor-γ; PSC: Pancreatic stellate cells.
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Pancreatic cancers 
The tumors of the pancreas are classified according to 
their origin in tumors of exocrine and neuroendocrine 
pancreas.
PCs originating from the neuro-endocrine com-
partment (pancreatic neuroendocrine tumor, PNET) 
contribute to 5% of the tumors and may (functional 
PNET) or may not (nonfunctional PNET) overproduce 
hormones[46,47]. About 50% of PNET are non-
functioning tumors that, conversely to functional PNET, 
are difficult to detect and are usually more malignant, 
with the reported percentage of malignant tumors as 
high as 90%[48]. 
Ninety five per cent of PCs are of exocrine origin 
and the most common form of all PCs is pancreatic 
ductal adenocarcinoma (PDAC) (see below for 
details). Others less frequent exocrine malignancies 
are the acinar cell carcinoma, the intraductal papillary 
mucinous neoplasm (IPMN) and the mucinous cystic 
neoplasms (MCN)[5,49,50]. Acinar cell carcinoma is a rare 
malignancy and differs significantly from PDAC, IPMN, 
and MCN, lacking their distinctive molecular alterations 
and presenting genomic alterations of its own[49-53]. 
Conversely, IPMN and MCN are considered benign 
cystic lesions that may develop to PDAC.
MCN is almost exclusively diagnosed in women, 
with a peak incidence in their 50s, as a single 
cystic lesion in the tail of the organ; the lesion is 
characterized by mucin-producing epithelial and show 
an ovarian-like stroma[50]. IPMN arise from ductal 
epithelium, appear as papillary projections in the main 
duct or in the branch ducts, and are almost equally 
distributed in men and women in their late 60s[49]. 
PDAC: Biology, precursor lesions, and therapy
PDAC alone contributes to about 90% of all PCs[54,55] 
which explain why PC and PDAC are commonly used 
as synonymous (as we will do henceforth). PDAC is 
characterized by the presence of several distinctive 
molecular alterations, the most frequent being 
activating mutations in the small GTPase Kirsten 
RAS (Kras)[56] but overall, at least 60 mutations in 13 
different molecular pathway have been described[53].
The progression model of PDAC points to a ductal 
origin of the disease with precursor lesions identified 
in the pancreatic intraductal neoplasia (PanIN). PanINs 
development is characterized by the early accumulation 
of genetic alterations found on PDAC, such as the Kras 
mutations and inactivation of the tumor suppressor 
p16; noteworthy, MCN and IPMN, although tumors on 
their own, may transform in PDAC and are considered 
among its potential precursors[5,57,58]. Quite recently, it 
has been proposed that PDAC may arise from acinar 
cells undergoing a transdifferentiation to ductal cells, in 
a process called acinar to ductal metaplasia (ADM)[59-61]. 
This idea is supported by the findings that in some 
animal models of PDAC, acinar cells are the focal point 
of PDAC growth acquiring the features of ductal cells 
AA at the N-terminus and for the tissue expression and 
overall activity: whereas PPARγ2 is localized only in the 
adipose tissue and is believed to be more adipogenic, 
PPARγ1 is more broadly expressed[18]. Recently, three 
new PPARγ transcripts were isolated (γ2ORF4, γ3ORF4, 
and more recently γ1ORF4)[16,17].
These new transcripts have different 5’-UTR but 
share exons 1-4, and harbor a readthrough in intron 
4, while lacking the exon 5-6; the resulting protein 
(γORF4) misses the LBD and acts as dominant 
negative NR. γ2ORF4 and γ3ORF4 transcripts were 
identified in sporadic colorectal cancer where γORF4, 
conversely to PPARγ, does not restrain cell growth but 
instead stimulates it[17]; 1ORF4 was later identified in 
adipocytes[16]. The existence of this dominant negative 
isoform suggests that PPARγ might possess a sort of 
self-regulation. Interestingly, the three transcripts 
may differentially contribute to adipose differentiation 
being γ3ORF4 constantly expressed along adipocyte 
differentiation but not in mature cells while γ1ORF4 
and γ2ORF4 exhibit stage-specific expression[16].
PPARγ was classified as an orphan NR until the 
discovery of its natural endogenous ligands, the 
prostaglandin 15-deoxy-delta (12, 14)-prostaglandin 
J(2) (15d-PGJ2) and oxidize lipids[19,31]. Rosiglitazone 
and pioglitazone are Thiazolidinediones (TZD), 
synthetic ligands of PPARγ: they are used for the 
treatment of diabetes and hyperlipidemia and have 
been investigated, together with other PPARγ ligands, 
in clinical trials for cancer and oxidative stress-related 
diseases treatment[5,32]. Besides PPARγ-dependent 
effects, TZD may act independently of PPARγ activation 
(i.e., the same effect mediated by TZD can't be 
obtained by PPARγ overexpression or the use of 
specific non TZD ligands) and PPARγ-dependent and 
PPARγ-independent effects may co-exist[33-36].
PPARγ is implicated in important biological processes 
ranging from regulation of metabolism to inflammation 
and differentiation; as such, PPARγ has been linked to 
several diseases including cancer[5,15,19,37,38].
PPARγ mechanisms of function comprises the 
standard arrays of activation/repression mechanisms 
of regulation of gene expression and transrepression. 
Interestingly, PPARγ being an ubiquitinase may 
regulate the function of different pathway, especially 
inflammatory, modulating the proteasome-mediated 
degradation of proteins[39,40].
PPARγ may be modified by post-translational 
modifications, such as phosphorylations operated 
by the MAPK p38 and JNKs, that may cause 
inhibition of transcriptional activity, alteration of 
localization and degradation[41-43]. These secondary 
modifications are important for PPARγ function: 
for example, phosphorylation of PPARγ at Ser273 
mediated by CDK5 in adipose tissue does not impair 
its adipogenic capacity but induces insulin resistance 
and is associated with a reduction of adiponectin 
secretion[44,45]. 
2444 February 28, 2016|Volume 22|Issue 8|WJG|www.wjgnet.com
Polvani S et al . PPARγ metabolic syndrome and PDAC
and expressing ductal markers[60,61]; furthermore, 
Kras activation in mature acinar cells induces PanIN 
lesions and coactivation of Notch/Kras promotes ADM 
phenotype, with Notch regulating both initiation and 
dysplastic progression of acinar-derived PanINs[62].
The PC is not among the 10 most frequent cancers 
neither in the US nor Worldwide and accounts for only 
a fraction of the totaling cancers[63,64]. However, with 
its incidence substantially equaling the mortality, PDAC 
is one of the deadliest cancer and the fourth cause of 
cancer death, which explains its importance in cancer 
research[63,64].
The high mortality rate is the consequence of 
essentially a combination of two factors: the delay in 
the diagnosis and the absence of an effective therapy. 
PDAC is a subtle disease: it is generally asym-
ptomatic or shows itself with aspecific symptoms 
that make difficult the diagnosis[65,66]. On one hand, 
malignant lesions possess clinical and imaging 
features similar to benign alterations of the pancreas: 
actually, cystic lesions are easily detectable but their 
presence is not suggestive of PDAC and the finding 
it not considered sufficient for surgical procedure 
due to morbidity and cost consideration; on the 
other hand the available biomarkers are plagued 
by low specificity and/or low sensibility[66-68]. Typical 
biomarkers for the detection and surveillance of 
PDAC are carcinoembryonic antigen (CEA) and 
carbohydrate antigen 19-9 (CA-19-9)[66-68]; both 
however are not exclusively expressed in PDAC and 
their use is limited to the surveillance of recurrence 
after surgical resection (CA-19-9) or as predictor of 
survival (CEA)[66-68]. Evaluation of new and improved 
biomarkers with prognostic and diagnostic value 
are currently ongoing in case-control studies[66]. The 
lack of specific biomarkers and efficient diagnostic 
systems for early detection is even more problematic 
for patient management because, conversely to other 
malignancies, PC has a tendency to dissemination 
even before tumor formation, as suggested by Rhim A 
in 2012[69]. Consequently, when a patient is diagnosed 
for PDAC, the disease may be already at an advanced 
stage, with local or distant metastasis, that precludes 
a successful surgical resection, the only effective 
therapeutic intervention. Even for patient eligible for 
resection the 5-years survival is around 20% whereas 
the 5-years overall survival for all patient is less than 
5%[63,64]. 
From 1996, the year of its approval, the treatment 
of PC is still preferentially based on the nucleotide 
analogue gemcitabine or its combination with other 
drugs, with modest results and important side-
effects[70]. Median overall survival in patients treated 
with gemcitabine is 5 mo and phase Ⅲ clinical trials 
have failed to improve this data[66,71]. In fact, until very 
recently, only a combined therapy with gemcitabine 
and Erlotinib, an EGFR inhibitor, demonstrated a 
modest increase in survival compared to gemcitabine 
monotherapy[72]. More recently, promising improvements 
have been made in the management of PDAC: two 
different phase Ⅲ trials have demonstrated that 
treatment of metastatic patients with Folfirinox or with 
nab-Paclitaxel plus gemcitabine significantly increases 
the survival, although folfirinox was associated to 
important toxic side effects[66,71,73-75]. 
An essential feature of PDAC is the presence of a 
“desmoplastic” reaction, i.e., the formation of a stiff 
fibrotic tissue around the tumor, consequential to the 
activation of pancreatic stellate cells (PSC)[76]. PSC, in 
response to TGF-β, PDGF, and other factors, proliferate 
and transform in myofibroblast-like cells expressing 
α-smooth muscle actin (α-sma); activated PSC 
produce an excess of extracellular matrix components 
creating the stiff stroma around the tumor[76-78]. The 
desmoplastic reaction is believed to be an impor-
tant factor for tumor chemoresistance; supporting 
this notion, in 2009 Olive et al[79] demonstrated in 
mouse models that the inhibition of the Hedgehog 
(Hh) pathway had beneficial effect on delivery and 
susceptibility to gemcitabine treatment. This seminal 
work was followed by the clinical trial IPI-926-03; 
designed to test the effect of the Hh inhibitor Saridegib 
on PDAC in association with gemcitabine, the trial 
was blocked after an interim analysis when it became 
evident that patients treated with gemcitabine and 
the placebo lived longer. Despite this failure, novel Hh 
inhibitors, like Sonidegib[80], have demonstrated to be 
effective in the treatment of cancers other than PDAC 
and are currently tested for PDAC; these efforts clearly 
suggest that the identification of an effective drug or a 
cocktail of drugs is today believed the best solution for 
PDAC treatment as a “systemic disease”. 
PDAC RISK FACTORS
PDAC development has been associated to several 
risk and co-morbidity factors. PDAC risk factors can 
be classified in modifiable and non modifiable risks: 
non modifiable risks are sex, age, presence of genetic 
mutations, ethnicity, whereas modifiable and co-
morbidity factors are related to the specific habits 
and lifestyle as well to the co-presence of other 
diseases[5,81-84]. PDAC is more frequent in men than 
in women, in elderly, and the presence of genetic 
mutations for examples in BRCA1, APC, or ATM genes 
increases the likelihood of PDAC development and 
is in agreement with the finding of the numerous 
genetic alterations characterizing the PDAC[53,81]. Of 
the modifiable risks, the more important is smoking, 
an habit that may also explain the increased risks 
associated to sex and ethnicity[81,82]. Recently it has 
become evident that obesity and diabetes are two 
important modifiable risk factors for PDAC, which we 
will discuss in details. 
PDAC is associated to diabetes
Glucose levels in the body are controlled by insulin 
and the insulin signaling pathway. Insulin is secreted 
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by pancreatic β-cell located in the islet of Langerhans 
in response to increased nutrients levels in the blood; 
insulin then determines the uptake of glucose (mainly) 
but also of free fatty acids (FFA) by muscle cells, 
hepatocytes, and adipocytes, for storage as glycogen 
(skeletal muscle and liver), lipids (adipocytes) and 
proteins[14,85]. 
Insulin acts on target cells mainly through insulin 
receptor (IR), a tyrosine kinase receptor that may 
also interact with insulin growth factor (IGF)[14,85]. IR 
is composed by two subunits (α and β) linked by di-
sulphide bonds: bind of insulin to the α-subunit leads 
to the β-subunit tyrosine autophosphorylation and to 
the phosphorylation of proteins belonging to the insulin 
receptor substrate (IRS) family and to SHC[86]. IRS 
interacts and activates the PI3K pathway and AKT which 
in turn phosphorylates and inhibits glycogen synthase 
kinase 3 whose main function in insulin pathway is to 
block the glycogen synthase, the enzyme that catalyze 
the final step in glycogen synthesis. Through SHC 
proteins insulin activates the p21RAS and the ERK 
signaling acting as a mitogen factor and through AKT 
insulin may activate mTOR[14,85,87]. Moreover, insulin 
regulates glucose uptake influencing the cellular 
localization of the Glucose transporter 4 (GLUT-4)[88,89]. 
In resting condition, around 5% of GLUT-4 is localized 
at the plasma membrane, while the majority is stored 
in the trans-Golgi compartment, in the so-called 
GLUT-4 storing vesicles (GSV)[88,90,91]. After insulin 
signaling, adipose and muscle cells respond increa-
sing the uptake of glucose through GSV exocytosis, 
mediated by PI3K-dependent and PI3K independent 
mechanisms[90,92]. 
Diabetes mellitus (DM) is a chronic disease that 
arises when the body is unable to regulate the 
levels of glucose. If not correctly treated, sustained 
increased glycemic levels are associated with renal 
failure, retinal damage, and cardiovascular diseases. 
In term of etiology, DM is distinguished in type 1 and 
type 2 diabetes. 
Type 1 diabetes is an autoimmune disease 
characterized by the destruction of β-cells as a 
consequence of adaptive immunity and innate 
inflammation and it is associated with a lack of 
insulin[93-95]; it is diagnosed in early childhood and 
may be treated with a life-long administration of 
insulin. Type 1 diabetes is often associated with other 
diseases such as autoimmune thyroiditis and celiac 
disease[93,95]. An increased number of evidence suggest 
that innate immunity mediated by Toll-like receptor 
(TLR) is implicated in the onset of Type 1 and Type 2 
diabetes[96,97].
Type 2 diabetes is by far the most common form 
of DM: ninety percent of diagnosis of diabetes are of 
type 2. DM type 2 is associated to insulin-resistance 
in a condition of normal or even higher levels of 
plasma insulin concentration[98]. Mechanisms behind 
insulin resistance vary from reduction of glucose 
transporter and IR expression to alteration of the 
insulin downstream signaling pathways and may 
be associated to genetic abnormalities, obesity and 
inflammation[99].
Other forms of diabetes are gestational diabetes, 
which may occur during pregnancy, and disease-
associated diabetes like diabetes occurring in pan-
creatic diseases. Indeed DM is a common finding 
in acute and chronic pancreatitis and in PC[100,101]. 
Chronic pancreatitis is characterized by a constant 
inflammatory reaction, activation of PSC and deposition 
of stromal fibers that usually evolves in pancreatic 
fibrosis and results in the destruction of Langerhans 
islets; interestingly, chronic pancreatic inflammation 
is associated to an elevated risk of PDAC[100,101], but 
it seems to be more important in the development 
of precursor lesions and in the initial stages of PDAC, 
given that anti-inflammatory drugs have not benefit 
in PDAC[102]. PDAC too is characterized by a stromal 
reaction and activation of stellate cells and diabetes 
is often a secondary effect of PDAC: nearly half of the 
patients with PDAC suffer from diabetes and its new 
on-set, especially if transient, might be suggestive of 
the neoplasm presence[103-106].
DM, especially the type 2, is a risk factor for several 
cancers and for PDAC[107]. The odds ratio to develop 
PDAC is 1.82 in diabetic patients and individuals with 
a recent diagnosis of DM have a 50% greater risk 
of the malignancy compared with individuals who 
had diabetes for more than five years[107]. These 
findings are corroborated by the demonstration that 
pancreatitis and diabetes increase the proliferation of 
pancreatic duct glands (PDG) and the production of 
PC-specific proteins in PDG[108].
Diabetes may facilitate tumor progression and growth 
increasing the availability of nutrients, e.g., glucose and 
FFA, increasing inflammation, or through the altered 
insulin signaling in hyperinsulinemia[103,105,106,109].
One of the key feature of tumor cells is the ability 
to switch the metabolic machinery towards the aerobic 
glycolysis (the Warburg effect), where pyruvate is 
preferentially metabolized by lactate dehydrogenase to 
lactate[110]. The Warburg effect might be an adaptation 
of pancreatic tumor cells to the relative hypoxia and 
metabolic constraints caused by the desmoplastic 
stromal reaction and it is also a key feature of the 
stromal compartment of the tumor[110]. On the other 
hand insulin resistance increases the circulating levels 
of lipids, especially FFA. FFA might have multiple 
effects: they constitute the building blocks of cell 
membrane and hence might favor tumor growth, they 
may be used as energy sources but may also cause 
oxidative stress, as much like as excessive glucose 
availability. The end products of oxidative stress 
are ROS and peroxidized lipids; although generally 
detrimental, ROS are important as signaling molecules 
in inflammation, immune cell response and invasion/
migration and are critical in Kras driven transformation 
in PDAC[111]. Finally FFA may induce inflammation 
activating the TLR signaling cascade[112].
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Experimental evidence point to a major role 
of insulin in the progression of several tumors 
and PDAC, independently from its effect on energy 
homeostasis[113,114]. PC cells express IR and the 
receptors for the insulin-growth factor (IGF)[109,115,116]. 
Conversely to insulin, IGF exerts mostly pro-
mitogenic and pro-survival effects through the ERK 
pathway, but insulin signaling may pass through IGFR 
and IGF may relay signals through IR[109,110,114,117] 
binding to IR-A, a fetal form of insulin receptor that is 
expressed in several cancers, including PDAC[109,118]. 
The interplay between insulin and IGF pathways 
is also suggested by the fact that IR and IGFR 
form hybrid receptors with affinity for insulin and 
IGF[85,109]. Moreover, high insulin levels may reduce 
the production of IGF binding protein by the liver 
increasing the bio-availability of IGF[119].
The role of diabetes and insulin has been recently 
demonstrated in a mouse model of hyperinsulinemia 
associated to DM type 2[108,120] where tumor growth 
is increased compared to control mice, in presence 
or absence of pancreatic inflammation induced by 
cerulein; in this model tumor growth was reduced by 
the anti-diabetic metformin[120], who as it turns out 
is also able to reduce the expression of cancer stem 
markers and to increase the expression of miRNAs that 
are typically lost in PC[121],in agreement with the finding 
that insulin could induce differentiation. Interestingly, 
in diabetic mice the inflammatory infiltrate is 
reduced compared to lean mice independently to 
cerulein treatment without difference in the overall 
inflammatory condition. These results suggest that 
tumor growth is mainly driven by hyperinsulinemia 
and not hyperglycemia, in agreement with models of 
DM type 1[122].
Obesity and PC
Mammalian body may store energy in the form of 
lipid droplets in the adipose tissue. Adipose tissue is 
mainly composed by adipocytes, cells specialized in fat 
accumulation, and by a small fraction of immune and 
stromal cells as well as pre-adipocytes. Traditionally 
we recognize two type of adipose tissue: the brown 
and the white adipose tissue. Brown tissue is localized 
in the cervical area, uses lipids to produce heat by 
thermogenesis, and decreases with aging[123]; white 
adipose tissue is implicated in obesity and is the main 
storing facility of lipids. When there is an unbalance 
between fat accumulation and fat mobilization the 
individual may become obese. The body mass index 
(BMI), that is the ratio of the body weight and the 
square of the height (in cm), is used to categorize 
individual in underweight, normal weight, overweight, 
and obese; when BMI is higher than 30 the individual 
is considered obese. Noteworthy, an important 
limitation of the BMI for the identification of overweight 
and obese individuals is that it does not account for the 
difference in the visceral fat and subcutaneous adipose 
tissues that are known to have different effects on 
health[124-127].
Obesity may arise from a plethora of causes but 
two are recognized as more important: overfeeding 
and low or even lack of physical activity. One of the co-
morbidity of obesity is DM type 2, that in association 
with metabolic changes induced by fat accumulation 
(e.g., abdominal obesity, high triglycerides content), 
constitutes a clinical condition known as metabolic 
syndrome.
One of the major problem of obesity, besides 
the induction of DM type 2 and increased risk of 
cardiovascular diseases, is its proved association 
with several cancers, including pancreatic[94,113]. 
These associations are worrying given that obesity is 
expanding in the developed and developing countries, 
reaching levels as high as 40% of the population 
(70% if counting overweight too), and its diffusion 
in childhood[94,128,129]. Obese individuals have an 
increased risk to develop PC, a higher chance to have 
a metastatic disease at the time of diagnosis, and a 
lower chance of survival, with a hazard ratio of death 
positively correlated with the duration of obesity[81]. 
The mechanisms underlying the association 
of obesity and PC are not well understood. It is 
postulated that obesity might increase the risk of 
PC altering the production of adipokines, inducing 
diabetes, altering the intestinal flora, and maintaining 
a sustained inflammation increasing the production of 
inflammatory cytokines[85,94].
Adipokines
Conversely to the common sense which bring to think 
to adipose tissue as a simple reservoir of energy in 
the form of fat, it has become evident over the years 
that the adipose tissue is actively involved in the 
regulation of the entire body metabolism. Indeed the 
adipose tissue acts as an endocrine organ secreting 
“adipokines”, molecules that may signal to metabolic 
active organs and to the central nervous system. 
Leptin and adiponectin are probably the better 
known adipokines but besides these two factors, 
adipose tissue may also produce resistin and other 
inflammatory citokines, an evidence that as brought 
many researchers to prefer the term “adipocytokines” 
when referring to the factors produced by the 
adipose tissue. Probably, it is the imbalance of these 
adipocytokines that increases the risks of the cancer of 
the pancreas in obese patients, as we will detail in the 
ensuing paragraphs, focusing our attention on leptin 
and adiponectin.
Leptin
Leptin is secreted by adipocytes and regulates appetite 
and energy metabolism acting mainly on the central 
nervous system and at the peripheral levels on cells 
expressing the leptin receptor (OBR). In the central 
nervous system leptin induces satiety and reduces 
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hunger, whereas the peripheral effects vary among 
target cells. In pancreatic β-cells for examples, leptin 
inhibits insulin secretion and synthesis in several ways 
(e.g., by reducing the expression of glucose-induced 
uncoupling-protein 2, by modifying PI3k pathway and 
cAMP)[130]; in turns, insulin induces leptin secretion 
and synthesis in adipose tissue[131]. Distinct OBR has 
been described: all are tyrosine kinase receptors and 
are similar in the extracellular domain but differ in 
the intracellular domain, and the OBRb is the longest 
isoform[132]. OBR are expressed in cancer cells and 
activate the downstream MAPK/ERK and STAT3 
pathways. Expression of leptin is correlated with 
the quantity of visceral adipose tissue and it is often 
associated to some sort of leptin resistance that causes 
hyperinsulinemia[131,133].
PC cells express OBRb and the shorter OBRa[134,135] 
and the overexpression of leptin in vivo is associated 
with increased tumor growth and metastatization[135]. 
In vitro, leptin increases migration through the up-
regulation of MMP13 mediated by JAK2/STAT3, and 
through the PI3K/AKT pathways. The role of leptin 
as an invasive modulator is also confirmed by the 
finding that OBRb expression correlates with MMP13 
and lymph node metastasis in primary tumors[135]. 
OBRb expression in PDAC cells in vitro is regulated by 
the hypoxia inducible factor 1α (HIF-1α) that bind to 
the OBRb promoter; this finding is corroborated by 
the demonstration that HIF-1α expression correlates 
with lymph node metastasis and OBRb in primary 
samples[136]. 
One of the feature of PDAC and other cancers is 
the induction of cachexia, a syndrome characterized 
by progressive loss of weight, an effect potentially 
mediated by leptin. However, Brown et al[137] demon-
strated that there was no association between 
patients with increased plasma leptin and weight loss 
or anorexia and a more recent metabolomic study 
suggested that PDAC patients with cachexia have 
lower leptin and higher interleukin (IL)-6 and TNF-α 
compared to PDAC patients without cachexia[138]. 
These results are in agreement with the finding 
that newly diagnosed PC patients have a decreased 
concentration of leptin compared to control or DM 
type 2 independently from age, BMI, and waist 
circumference[132,139]. On the contrary, the ratio 
adiponectin/leptin and the level of resistin, another 
adipokine, are increased in PDAC patient[132,139]. 
It is tempting to speculate that leptin role in 
PDAC is primary associated to the induction of 
metastatization and may be linked to its ability to 
function as a pro-inflammatory cytokine. Indeed 
leptin is structurally similar to IL-6, also produced 
by the adipose tissue; IL-6 is a pro-inflammatory 
cytokine that increases invasion and migration and 
epithelial to mesenchymal transition (EMT) of PC cells, 
and synergies with leptin acting on STAT3[8,140,141]. 
Moreover the hypothesized role of leptin as a pro-
metastatic agent is demonstrated also by its ability to 
induce cell invasion in ovarian, prostate, gastric, and 
breast cancers, and to induce EMT in A549 lung cancer 
cells[142-147]. 
Adiponectin 
Adiponectin is another adipokine produced primarily 
by adipocytes which resembles the C1q, a protein 
of the complement system[148,149]. Adiponectin may 
also be secreted by other cells, like lymphocytes 
and skeletal muscle cells; however it is believed 
that their contribution to circulating adiponectin is 
limited[124,150,151]. Adiponectin undergoes to several 
secondary modifications that influence secretion, 
multimerization, and clearance, ranging from glycosylation, 
succination, and thiol modifications[152]. Adiponectin 
is secreted by adipocytes as a high molecular weight 
protein oligomers (HMW), low molecular weight 
oligomers (LMW), medium weight multimers and 
monomers[152] and may be cleaved by the leukocytes 
elastase to generate the globular adiponectin[152]. 
Two adiponectin receptors (AdipoR1 and AdipoR2) 
have been described: they show different affinity 
for HMW, LMW and monomers, and different tissue 
distribution. AdipoR1 has high affinity for the globular 
adiponectin, whereas the more metabolically active 
HMW binds preferentially to AdipoR2. Activation 
of the receptors may results in different effects 
mediated by AMPK and the p38 MAPK[153]. Noteworthy, 
AdipoR2 induces the activation of the nuclear 
receptors PPARγ and PPARα[153,154]. Activation of the 
adiponectin pathway has several effects: reduces liver 
gluconeogenesis but increases liver utilization of FFA 
by β-oxidation, increases adipocytes uptake of FFA, 
and increases insulin sensitivity acting at many levels. 
Adiponectin has also anti-inflammatory effects and an 
inflammatory condition reduces this adipokine[126,151,153]; 
the mechanisms underlying these associations are 
complex and may be linked to the regulation of PPARγ. 
Adiponectin elicits opposite effects compared to 
leptin and its levels are inversely correlated to BMI and 
to the presence of diabetes[155]. 
Interestingly, activation of the downstream adipo-
nectin pathway results in inhibition of leptin signaling 
blocking the Jak and STAT3 phosphorylation[113,156]; 
besides the metabolic effects, this interplay may be 
important in the formation of the PDAC desmoplastic 
reaction following PSC activation (see later for details).
In cancer, whereas leptin is usually pro-angiogenic, 
pro-proliferative, and pro-invasive, adiponectin reduces 
proliferation, invasion and angiogenesis[124,144,145,147,153]. 
Indeed, low adiponectin levels are a common finding in 
tumors and correlate with tumor stage; this happens 
for breast, prostate and liver cancer and has been 
reported for PDAC. However, the association PDAC-
adiponectin is not clear: both low and high adiponectin 
has been linked to an increased cancer risk[132,155,157-160]. 
In two case-control studies higher adiponectin and 
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lower leptin levels were associated to the presence of 
PDAC, before and after controlling for co-factors such 
as BMI and smoke; moreover PDAC patients have 
high adiponectin compared to chronic pancreatitis 
and control[157,158]; interestingly, AdipoR1 and AdipoR2 
are also high expressed in PDAC and the adiponectin/
leptin ratio is higher in cancer patient compared to 
healthy and DM type 2 patients[132,157]. Conversely, 
a prospective study demonstrated that low pre-
diagnostic levels of this adipokine were associated 
to an elevated risk to develop PDAC[159]. Another 
perspective study concluded that pre-diagnostic 
levels of adiponectin were not predictive of PDAC 
development in the general population but lower levels 
in never smokers were associated to increased risk 
of PDAC[155]; finally a study in Finnish male smokers 
supports these previous cited works showing that 
higher adiponectin concentration was inversely 
associated to PDAC[160]. 
There are not clear reasons behind these different 
findings. It is possible to speculate that they may 
be caused by differences in the studied population 
but another possible explanation may be that these 
studies are inherently different being prospective and 
case-control. Indeed low levels of adiponectin are 
associated to obesity and DM type 2 that predispose 
to PDAC and the high adiponectin detected in case-
control studies might be a compensatory mechanisms 
to insulin resistance and cachexia in more advanced 
stages. Furthermore, it is also conceivable that the 
differences are associated to genetic variants of 
adiponectin gene ADIPOQ and not to its expression 
levels. Two independent works published in the last 
two years have demonstrated that specific single 
nucleotide polymorphisms (SNP) might predispose 
or protect from PDAC: the two groups analyzed the 
expression and association of the DM type 2 associated 
SNP rs1501299 of the ADIPOQ gene showing that the 
CC and AC genotypes are associated to a higher risk 
compared to the AA genotype[161,162]. 
On the other hand it has been demonstrated that 
adiponectin protects β-cells of the Islet of Langerhans 
from apoptosis activating the ERK and AKT pathways, 
without altering the AMPK pathway, and independently 
from AdipoR signaling; furthermore, adiponectin 
induces insulin synthesis and secretion[163]. 
Association of adiponectin levels to PDAC has 
been extensively studied in vitro and in vivo. One of 
the most used animal model in PC research is the 
KrasG12D/Pdx-1-Cre mouse model. In this mouse, 
the Cre recombinase, under the control of the Pdx-1 
promoter, induces the expression of the constitutively 
active KrasG12D as early as 8.5 d.p.c. in a common 
precursor of pancreatic exocrine and endocrine cells. 
The KrasG12D/Pdx-1-Cre mouse develops ductal lesions 
identical to human PanIN lesions and the pancreas 
shows extensive desmoplastic and inflammatory 
reaction; within 1 year the mouse lesions progress 
to PDAC[164]. In KrasG12D/Pdx-1-Cre mice, chronic 
or intermittent calorie restriction delays tumor 
progression but increases the expression of Sirt1 
and serum adiponectin while reducing leptin[165]. 
These results are in agreement to similar findings 
on cancer cells of different origins and are confirmed 
by the demonstration that adiponectin treatment 
of murine Pan02 PC cells in vitro modestly reduces 
cell proliferation and increases apoptosis, and that 
orthotopic transplantation of the same cells in 
knockout adiponectin mice results in increased tumor 
growth[166].
Nonetheless, Huang et al[26] have suggested that 
adiponectin conversely promotes cancer progression. 
Using a similar mouse models but different cell lines, 
the Authors demonstrated in vivo that adiponectin 
deficiency markedly reduced tumor growth and that 
adiponectin reduced apoptosis throughout AdipoR1 
but not AdipoR2. The downstream surviving pathway 
involves the phosphorylation of AMPK and increased 
expression of Sirt1 which in turn deacetylates 
proliferator-activated receptor gamma co-activator 
1-a (PGC1a) altering the expression of mitochondrial 
genes[26,27]. 
These opposite results may be associated to 
differences in the experimental animal models: 
indeed whereas Kato et al[166] used an orthotopic 
model, Haung et al[26] performed subcutaneous 
tumor engraftment; it might also be possible that 
in the tested cell lines adiponectin signaling may be 
transmitted preferentially by one of the two AdipoR 
who we know activate different signaling cascades. 
Anyway, these in vivo discrepancies reflect the 
uncertainty in the epidemiological data and certainly 
point out that more work need to be done to ascertain 
the role of adiponectin in PDAC development.
PPARγ AND PC 
The research of a causative association of the NR 
PPARγ to PDAC has been the subject of intense 
research. These efforts are mainly driven by the 
tempting idea to apply TZD or other PPARγ-targeted 
drugs to the therapy of this disease (for recent reviews 
see[5,167,168]) and it is based on the assumption that 
PPARγ is a key metabolic regulator and play an anti-
inflammatory role inhibiting the pro-inflammatory NF-
κB, STAT and AP-1 pathways[18,19].
In vitro results are promising and point out to an 
inhibitory role of PPARγ. Treatment of PC cells with 
PPARγ agonists induces apoptosis, ductal differentiation 
and arrest cells in G0/G1 phase by PPARγ -dependent 
and -independent mechanisms[33-35]. PPARγ may also 
reduce cell motility and invasion altering the expression 
levels of component of the urokinase plasminogen 
activator (uPA) system, the catenin p120 localization 
and suppressing Cdc42 and RAC1[169,170]. UPA system 
is implicated in the remodeling of the extracellular 
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matrix and casually involved in multiple steps of cancer 
development[171]; in PDAC, PPARγ agonists alter the 
total urokinase activity by increasing the expression of 
uPA inhibitor-1 and decreasing uPA[170]. 
These results are confirmed by in vivo experiments 
where PPARγ reduces tumor growth and enhances the 
gemcitabine effects possibly modifying the Notch and 
NF-κB- dependent inflammatory environment and 
the desmoplastic reaction[5,172,173]. In rectal xenograft 
models pioglitazone-mediated suppression of tumor 
spreading was paralleled by IL-8 and Cox-2 mRNA 
reduction in vitro[174]; although the effects of Cox-2 in 
PDAC cancer are highly associated to its expression 
levels, this inducible enzyme is regulated by PPARγ and 
may metabolize arachidonic acid to produce precursors 
of PPARγ ligands creating a positive feedback loop[19]; 
interestingly, PPARγ agonists and Cox-2 inhibitors 
may synergize and may be exploited for PDAC 
treatment[175,176]. 
Other synergisms and interactions with pathways 
involved in PDAC has been described in the literature: 
for examples, PPARγ activation contemporary to 
the inhibition of IFN-β or the administration of RXR 
agonists increases the anti-proliferative effects on 
PDAC cells[5] or, moving away from PDAC, PPARγ may 
interact with NRF2 to ameliorate and respond to ROS 
stress (for a recent review see[19]). 
Alteration of E3 ubiquitin ligases is associated to 
the development of several diseases and pancreatic 
neoplasms[39,40,177]. Interestingly, PPARγ is a NR but 
is also an E3 ubiquitin ligase; as ubiquitin ligase 
PPARγ may play an important role in the regulation of 
PDAC development: it has been demonstrated that 
PPARγ may terminate the pro-inflammatory response 
mediated by NF-κB, targeting p65 for nuclear export 
and degradation[39], and may induce the proteasome-
dependent degradation of the MUC1-C oncoprotein, 
one of several mucins involved in cell proliferation and 
invasion[40]. 
Besides in vitro and in vivo data, analysis of 
primary tumors clearly show that the NR is expressed 
at high levels in the neoplasms[33,178-180]. The expression 
of PPARγ is inversely correlated to the overall survival, 
the higher the expression the shorter the survival, 
especially in patients who received chemotherapy 
after surgery; conversely, PPARγ expression directly 
correlate with TNM stage[33,178-180], suggesting that 
PPARγ is a critical target for PDAC treatment. 
CROSSROAD
PDAC is a subtle and difficult to treat systemic disease. 
We have shown that diabetes and obesity, and by 
extension systemic metabolic disease, are important 
risks factors for the neoplasm. Finding a way to tackle 
the risks factors to prevent the PDAC is an obvious 
therapeutic strategy; even more interesting would be 
find a target, or possibly targets, shared by these risks 
and PDAC: PPARγ is a possibility, and we will show you 
why.
The metabolic syndrome comprises a spectrum of 
factors and may cause damage and promote PDAC 
in several ways, including lipid toxicity and increased 
inflammatory response, linked to insulin resistance and 
obesity. The benefit of TZD treatment and activation of 
PPARγ range from improved insulin-sensitivity, alteration 
of lipid metabolism and adipocytes differentiation, and 
reduction of inflammation as a direct consequence of 
the modification of adipose tissue metabolism.
The PPARγ agonists TZD have been widely used in 
the treatment of DM type 2 to ameliorate the insulin-
resistance. As we previously mentioned, increased 
insulin production comes with several side effects 
and it is a risk of PDAC, associated with increased 
availability of glucose and oxidative stress, not to 
mention that insulin may act as a mimetic mitogen. 
PPARγ and insulin are tightly related and activation 
of PPARγ results in increased insulin sensitivity. When 
compared to metformin, the NR agonists have several 
advantages modulating insulin signaling cascade at 
different levels.
First of all, it has been demonstrated that PPARγ 
regulates insulin production and synthesis in β-cells. 
PPARγ indirectly regulates the insulin transcription 
mediated by PDX-1. PDX-1 is a master regulator 
of pancreas development and differentiation and in 
β-cells it regulates the expression of insulin gene. 
Interestingly, PDX-1 is a target gene of PPARγ[38,181] 
and treatment of rat insulinoma cells Ins-1 with 
TZD increases the expression of Nkx6.1, another 
transcription factor implicated in insulin transcription[38]. 
Insulin secretion by β-cells is mainly dependent 
on the activation of ATP-sensitive potassium channel 
(K-ATP): building up of glucose in the β-cells increases 
the ATP/ADP ratio and brings up to the closure of 
K-ATP channels followed by membrane depolarization 
and influx of Ca2+ from ER and extracellular space: 
the end result of this process is the fusion of insulin-
containing vesicles with the plasma membrane and 
insulin secretion. PPARγ increases insulin secretion in 
β-cells regulating the expression of G-protein-coupled 
transmembrane receptor 40, a FFA receptor (for a 
review of FFA role on insulin secretion see[182]), and 
possibly through the up-regulation of the cholesterol 
transporter ATP-binding cassette transporter A1 whose 
expression is increased after TZD treatment. On the 
other hand PPARγ also induces the expression of 
GLUT-2 and GLUT-4 and of other glycolytic enzymes 
that influence the ATP/ADP ratio[183-185]. 
Moreover PPARγ may ameliorates DM type 2 
increasing the insulin sensitivity in the peripheral 
tissues. PPARγ increases the uptake of glucose in the 
skeletal and adipose tissue by regulation of glucose 
transporters and might increases insulin signaling 
modulating AMPK, much as metformin[87]. Activation 
of AMPK increases muscle glucose uptake, reduces 
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liver gluconeogenesis and hepatic glucose output as 
well as increasing fatty acid oxidation, generally promo-
ting catabolic events to produce ATP[14,87]. mTORC 
inhibition and p53 activation follow AMPK activation 
and interestingly this is a key mechanism used by 
adiponectin to oppose leptin effects[156]. 
Nonetheless it is supposed that the main effect 
of TZD and PPARγ is primarily due to the increased 
insulin secretion by β-cells and activation of lipid and 
glucose metabolism in adipocytes and only secondary 
to the metabolic effects on liver and skeletal muscle, a 
hypothesis that bridges DM type 2 to obesity.
PPARγ is a master regulator of adipocytes diffe-
rentiation. Pre-adipocytes are maintained in un-
differentiated state by the Wnt/β-catenin pathways 
that activates the expression of COUP-TFⅡ NR which 
recruits the SMRT corepressor complex to repress 
PPARG1 and PPARG2 gene[186]. Interestingly, a 
regulatory network linking activation of β-catenin to 
PPARγ has been hypothesized to participate in the 
resistance to oxidative stress[19]. 
Obesity is characterized by accumulation of 
visceral adipose tissue that produces high quantities of 
inflammatory cytokines, mainly leptin but also IL-1β, 
TNF-α, IL-8, IL-6[187]. In adipocytes, PPARγ activation 
has been associated to the up-regulation of IRS-2 
and CAP components of insulin pathway and hence to 
increased insulin-sensitivity[188,189].
Activation of PPARγ in pre-adipocytes leads to the novo 
differentiation of subcutaneous adipocytes accompanied 
by apoptosis of older visceral adipocytes[28,190]. Despite 
the overall risk of increased body weight in patients 
treated with TZD, redistribution of lipid and fat from 
visceral to subcutaneous depots has advantages in 
the long term: the new adipocytes are smaller and 
more insulin-sensitive. Formation of new adipocytes 
also reduces the concentration of circulating FFA and 
brings to a concomitant reduction of lipotoxicity both 
in β-cells and in pancreatic tissues whose infiltration by 
lipid-containing cells is associated to increased risks of 
developing PanIN lesion[191]. Moreover the new adipose 
tissue produces higher amounts of anti-inflammatory 
adiponectin and lower of leptin. Production of both 
adipokines is under direct and indirect control of 
PPARγ: leptin expression is indirectly reduced by PPARγ 
by antagonism on leptin promoter with C/EBP whereas 
adiponectin is under direct control of the NR that 
also induces the secretion of HMW adiponectin from 
adipocytes[192].
Moreover, in mice PPARγ and C/EBP synergize 
to induce adipocyte-specific expression of resistin, 
another adipokine associated with inflammation 
and DM type 2[193]. Noteworthy, in human the main 
source of resistin are macrophages and PPARγ inhibits 
resistin synthesis[194]. Macrophages can acquire 
distinct phenotypes depending on the stimuli they 
receive from the environment: the M1 is considered 
an inflammatory phenotype whereas the M2 macro-
phages are considered anti-inflammatory[195,196]; 
interestingly, adipose tissue in obese and DM type 2 
patients is characteristically rich in M1 macrophages. 
PPARγ primes primary human monocytes into M2 
differentiation but does not influence M2 marker 
expression in resting or M1 macrophages, and 
regulates the expression of CD36, a scavenger 
receptor that recognize oxidized lipids and is an 
hallmark of M2 phenotype[19,196].
Apart from regulating levels of the classic 
adipokines adiponectin and leptin, PPARγ may suppress 
the production of the pro-inflammatory cytokines 
TNF-α, IL-6, PAI-1, in adipose tissue. Suppression of 
these cytokines is associated with the repression of NF-
κb signaling cascade. It is well known that PPARγ and 
NF-κB interact in several ways. PPARγ transrepresses 
NF-κB acting as a transcriptional co-repressor of 
NF-κB-target genes or by direct binding with NF-
κB[19,197,198]; moreover the nuclear receptor may reduce 
NF-κB activation and even induce its degradation[39]. 
PPARγ inhibits NF-κB signaling also in immune 
cells, an inhibition that results in a substantial anti-
inflammatory response. Conversely, NF-κB negatively 
regulates PPARγ transcriptional activity through histone 
deacetylase 3[19].
We may hypothesize that these systemic beneficial 
alterations are accompanied by a protective and 
anti-tumorigenic effects on PDAC. Indeed, as we 
previously described, experimental evidence suggest 
that PPARγ might be protective against PDAC, 
reducing tumor growth and metastatization and 
inducing apoptosis, and patients treated with TZD 
have a lower risks to develop cancer[113]. As we cited 
previously, PPARγ activation results in modulation of 
AMPK and interestingly in cancer cells AMPK activation 
suppresses and reverses EMT by modulating the AKT-
MDM2-Foxo3 signaling pathway and hence blocking 
the metastatization of cancer cells[199]; this evidence 
suggests that PPARγ-direct inhibition of metastatization 
might be reinforced indirectly by other genes.
The inhibition of inflammation and the reduction 
of ROS and oxidative stress is also important in tumor 
progression impairing given that production of ROS 
is necessary in Kras mediated tumorigenesis[111]. 
We have previously noted that PSC activation is a 
typical feature of PDAC and the ensuing desmoplastic 
reaction constitutes a bivalent cellular habitat. Indeed, 
Apte et al[76] proposed that in the earliest stages of 
carcinogenesis PSC activation could represent an 
attempt to initially restrict tumor growth while later 
on PDAC development cancer cells subvert PSC into 
cancer-permissive cells protecting tumor growth. 
PPARγ is important in maintaining PSC in their 
“quiescent” vitamin A phenotype and hence activation 
of PPARγ could theoretically impair PSC activation 
and the formation of a permissive cancer habitat. 
This effect could be strengthened by the alteration of 
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adipokines: indeed leptin signaling is pro-fibrogenic 
and sustains the proliferation of liver stellate cells 
facilitating the M phase as well as altering the levels 
of TIMP factors; conversely, adiponectin in stellate 
cells induces apoptosis and reduces the expression of 
collagen 1α1[200]. 
Although the mechanisms linking obesity and 
diabetes to PDAC are not fully understood, we have 
described strong experimental evidence showing that 
the adopted nuclear receptor PPARγ is implicated in 
the three process. Being at the cross-road of these 
interlinked diseases PPARγ is a strong candidate for 
a combined therapeutic approach devoted to the 
prevention and to the treatment of PDAC in obese and 
diabetic patients.
CONCLUSION
As a concluding remark, PPARγ agonists may be 
and are used to treat insulin-resistance with great 
effect, technically and theoretically they may be used 
to ameliorate the obesity and obesity-associated 
inflammation and the desmoplastic reaction, they 
have proven to be effective both in vitro and in vivo 
in the treatment of PDAC. And so, may we conclude 
that PPARγ is the perfect choice and we have a cure for 
these diseases? Unfortunately, not now, not yet.
What is still missing is a precise understanding of 
the association of these diseases and more importantly 
a safer and effective PPARγ agonist to be used for 
the treatment of metabolic syndrome, inflammation, 
and PDAC. Clinical use of PPARγ agonists for PDAC 
treatment never passed clinical trials although TZD are 
used for diabetes[28,113].
As it stands out, PPARγ if not the “perfect choice” 
is as far as it gets a “good choice” that could become 
“perfect” if and when a drug with a safer profile and no 
PPARγ-independent effects will be discovered. 
At least, PPARγ is a start. 
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